Patent · US Expired

Method to treat pulmonary hypoplasia in the newborn

US6939534B2 · kind B2 · utility

1Cited by
4References
5Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 8, 2002
Grant dateSep 6, 2005
Priority date—
Expiry dateMar 10, 2023

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/0034
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.